Research Funding availability
UK Dermatology Clinical Trials Network (UK DCTN)- Three £10K awardsfor research related to paediatric dermatology
The UK DCTN annual themed call award is designed to provide assistance to study teams developing research that may lead to a full clinical trial. Applications can include work related to outcome measures, pilot/feasibility work and research priority setting. If you have a project relating to skin disease in children, please see the terms and conditions on the UK DCTN website and apply now. Closing date for applications – Mon 19 July 2021
This research is co-funded by the BSDP, UKDCTN and the National Eczema Society, 1 x £10,000 award is ring-fenced for paediatric eczema research, while the other two awards are available for any topic relevant to paediatric dermatology (including eczema).
Only UK applicants are eligible, and you must be available to present your idea, if shortlisted, on 5th October 2021.
Did you know that children with psoriasis may be eligible for the BADBIR study?
Since October 2015, BADBIR has been accepting enrolment of paediatric patients with psoriasis.
As these patients are being exposed to immunosuppressive therapy on a comparatively immature immune system, it is important that the long term safety is evaluated. In addition, there is potentially a high lifetime exposure to these therapies which may place them at a higher risk than adults.
Currently BADBIR’s recruitment total for participants is only around 30 registrations across the whole of the U.K. and Ireland with just 16 centres contributing. We understand that it is possible that you are not necessarily managing these patients in your clinics but please could you liaise with colleagues to explore the feasibility of registering these eligible patients.
Full details of the eligibility criteria for paediatric patients on BADBIR can be found at http://www.badbir.org/Clinicians/Eligibility/
If you require any assistance or advice please contact the BADBIR study team at email@example.com or on 0161 306 1896.